Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355655 | 0.87 | CDK8 (0.41) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL1714854 | 0.86 | KIF11 (0.51) | LMNAKDM4ECYP3A4ACHEPOLB | |
| SCHEMBL18697357 | 0.86 | CDK8 (0.44) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL17352128 | 0.86 | CDK8 (0.44) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL10181523 | 0.86 | LMNA (0.47) | LMNAKDM4ECYP3A4ACHEPOLB | |
| SCHEMBL17352175 | 0.86 | CDK8 (0.44) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL17356448 | 0.85 | ELANE (0.47) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL23771609 | 0.84 | HTR2A (0.40) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL17352134 | 0.84 | ELANE (0.44) | HTR2ASLC6A4KCNH2CDK8AR | |
| SCHEMBL17352138 | 0.83 | CDK8 (0.43) | HTR2ASLC6A4KCNH2CDK8AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | claimed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7375102-B2 | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use | AMGEN SF, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| CN-101006088-A | Fused pyrimidine derivatives and compositions thereof as CXCR3 receptor modulators for the prevention and treatment of inflammatory and immunomodulatory disorders and diseases | AMGEN SF LLC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1341774-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6545155-B2 | Useful for increasing insulin secretion in the treatment of type II diabetes | HOFFMANN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-6448399-B1 | 3-CYCLOALKYL- OR PROPYL-2-(3,4-DIHALOPHENYL)-N-QUINOLINYL-, QUINAZOLINYL-, OR QUINOXOLINYL-PROPIONAMIDE. | HOFFMANN-LA ROCHE INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441184-B1 | SUCH AS N-BENZOOXAZOL-2-YL-3-CYCLOPENTYL-2-(4-METHANESULFONYL -PHENYL)-PROPIONAMIDE FOR INCREASING INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | LMNA 4732/4885HTR2A 2591/4885SLC6A4 3229/4885 |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | GCKR, GCK, GPR119 | LMNA 4732/4885HTR2A 2591/4885SLC6A4 3229/4885 |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | HCN2, SCO2, HCN1 | LMNA 1291/4885HTR2A 4567/4885SLC6A4 2741/4885 |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | LMNA 4732/4885HTR2A 2591/4885SLC6A4 3229/4885 |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | P2RX7, P2RX3, P2RX1 | LMNA 2320/4885HTR2A 204/4885SLC6A4 292/4885 |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | LMNA 4732/4885HTR2A 2591/4885SLC6A4 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.